Top-notch Nkarta stock tumbled Friday after the biotech company deprioritized a cancer drug in favor of an experimental lupus treatment.
The post Why Top 1% Biotech Stock Nkarta Just Plummeted, Undercutting Its 50-Day Line appeared first on Investor’s Business Daily.